The recently opened Judi and Bill Leonard Institute for Cancer Prevention, Treatment and Wellness at Mission Hospital in Mission Viejo has announced a partnership with new Orange County public company OncoCyte Corp. to use its product DetermaRx.
DertermaRx is a diagnostic test used to determine whether a patient’s cancer will be receptive to chemotherapy postoperatively and can rule out malignancy in lung nodules.
Under the current standard of care, about 30% to 50% of Stage I to IIA patients who have had surgery to remove lung tumors tend to experience a cancer recurrence and die within five years of surgery.
Mission Hospital, whose cancer center opened in November, said its access to DetermaRx allows high-risk patients to receive chemotherapy immediately after surgery to help better overall health outcomes and survival rates.Â
“Our early access partnership with DetermaRx allows us to enhance our comprehensive lung cancer treatment program and optimize post-surgical treatment decisions,” Chief Executive Seth Teigen said.
The Business Journal was first to report on Oncocyte (NYSE: OCX), which has a $160 million market cap, relocating from Alameda to OC, in the Jan. 13 print edition.
